Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 5/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | F2 | P00734 | 2/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 2/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 2/20 | 0.46 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31294149 | 0.85 | KMT2A (0.53) | GPR35KMT2AMEN1TSHRCA2 | |
| SCHEMBL3193995 | 0.85 | KMT2A (0.68) | GPR35KMT2AMEN1TSHRCA2 | |
| SCHEMBL27412106 | 0.83 | CA2 (0.44) | GPR35KMT2AMEN1TSHRCA2 | |
| SCHEMBL4158554 | 0.82 | KMT2A (0.70) | KMT2AMEN1CA2CA9F2 | |
| SCHEMBL370668 | 0.82 | KMT2A (0.70) | KMT2AMEN1CA2CA9F2 | |
| SCHEMBL8565033 | 0.81 | KMT2A (0.53) | GPR35KMT2AMEN1TSHRCA2 | |
| SCHEMBL31294204 | 0.81 | KMT2A (0.53) | GPR35KMT2AMEN1TSHRCA2 | |
| SCHEMBL31294234 | 0.81 | KMT2A (0.53) | GPR35KMT2AMEN1TSHRCA2 | |
| SCHEMBL7531981 | 0.81 | CA2 (0.59) | GPR35KMT2AMEN1CA2CA9 | |
| SCHEMBL7531976 | 0.81 | KMT2A (0.53) | GPR35KMT2AMEN1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119798210-B | Preparation method of high-purity glycolide | 山东金特安全科技有限公司 | 2025-05-20 | — | — | CN | claimed |
| CN-119798210-A | Preparation method of high-purity glycolide | 山东金特安全科技有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-108586735-A | A kind of releasable SO2Polymer, preparation method and its application and nano-micelle | 中国科学院长春应用化学研究所 | 2018-09-28 | — | — | CN | claimed |
| WO-2013102936-A1 | N-(3-((DIETHYLAMINO) METHYL)-4-HYDROXYPHENYL)-N-(QUINOLIN-4-YL) SULFONAMIDES FOR THE TREATMENT OF TUBERCULOSIS AND PROCESS OF PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-07-11 | — | — | WO | claimed |
| US-20260138946-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | CURIA SPAIN S A U (ES) | 2026-05-21 | — | — | US | disclosed |
| US-12552746-B2 | Process and intermediates for the preparation of upadacitinib | CURIA SPAIN, S.A.U. (ES) | 2026-02-17 | — | — | US | disclosed |
| US-12543674-B2 | Embryogenesis factors for cellular reprogramming of a plant cell | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 2026-02-10 | — | — | US | disclosed |
| US-20250277230-A1 | PARTHENOGENESIS METHODS AND COMPOSITIONS | PIONEER HI-BRED INTERNATONAL, INC. (US) | 2025-09-04 | — | — | US | disclosed |
| CN-119798210-B | Preparation method of high-purity glycolide | 山东金特安全科技有限公司 | 2025-05-20 | — | — | CN | disclosed |
| CN-115151529-B | Processes and intermediates for preparing Wu Pati n | 库里亚西班牙公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-119798210-A | Preparation method of high-purity glycolide | 山东金特安全科技有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20250115924-A1 | SYSTEMS AND METHODS FOR CELLULAR REPROGRAMMING OF A PLANT CELL | PIONEER HI-BRED INTERNATIONAL, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| EP-1216227-A2 | PREPARATION OF SULFONYL IMINE COMPOUNDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2002-06-26 | — | — | EP | disclosed |
| US-6380429-B1 | OXIDATION OF SULFONAMIDE | E. I. DU PONT NEMOURS AND COMPANY | 2002-04-30 | — | — | US | disclosed |
| WO-2001023352-A2 | PREPARATION OF SULFONYL IMINE COMPOUNDS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2001-04-05 | — | — | WO | disclosed |
| EP-0949238-A1 | SUBSTITUTED PROPIONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1999-10-13 | — | — | EP | disclosed |
| EP-0616609-A1 | NITROANILINE DERIVATIVES AND THEIR USE AS ANTITUMOR AGENTS. | CANCER RES CAMPAIGN TECH (GB) | 1994-09-28 | — | — | EP | disclosed |
| CN-1047220-A | PAN GRANULATION | DU PONT (US) | 1990-11-28 | — | — | CN | disclosed |
| US-4897423-A | Dinitrobenzenesulfonamides | MERCK & CO. INC. (US) | 1990-01-30 | — | — | US | disclosed |
| EP-0037030-A1 | Aromatic diamines containing sulphon amide groups | BAYER AG (DE) | 1981-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138946-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | JAK1, JAK3, JAK2 | GPR35 4678/4885KMT2A 679/4885MEN1 348/4885 |
| US-12552746-B2 | Process and intermediates for the preparation of upadacitinib | JAK1, JAK3, MET | GPR35 4728/4885KMT2A 686/4885MEN1 260/4885 |
| US-12543674-B2 | Embryogenesis factors for cellular reprogramming of a plant cell | CCNB2, CCNB1, CCNB3 | GPR35 4200/4885KMT2A 2450/4885MEN1 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.